dolutegravir/lamivudine vs sucralfate
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of dolutegravir/lamivudine and sucralfate. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Medications containing polyvalent cations (e.g., Mg or Al): Cation-containing antacids a or laxatives Sucralfate Buffered medications ↓Dolutegravir Administer DOVATO 2 hours before or 6 hours after taking medications containing polyvalent cations.
Dovato
Carafate
Dovato is a complete HIV-1 treatment that combines two medicines into one tablet. It is used for adults and adolescents who weigh at least 55 pounds.
Sucralfate is a medicine that helps heal and protect ulcers in your small intestine. It creates a coating over the ulcer to shield it from stomach acid.
Dovato is used to treat HIV-1 infection in adults and adolescents (12 years and older, weighing at least 55 pounds). It can be used if you have never taken HIV-1 medicines before. It can also be used to replace your current HIV-1 medicines if your virus is under control (HIV-1 RNA less than 50 copies/mL) and you have not had treatment failure or resistance to the medicines in Dovato.
Sucralfate is used to treat active duodenal ulcers, which are sores in the first part of your small intestine. It can help heal these ulcers over a period of 4 to 8 weeks. Sucralfate can also be used as maintenance therapy at a lower dose to prevent ulcers from coming back after they have healed.
Dovato contains two drugs: dolutegravir and lamivudine. Dolutegravir blocks HIV-1 integrase, an enzyme the virus needs to multiply. Lamivudine blocks reverse transcriptase, another enzyme HIV-1 needs to make copies of itself.
Sucralfate works by forming a protective layer over the ulcer. This coating acts like a bandage, shielding the ulcer from stomach acid and enzymes. This protection helps the ulcer heal.
- • Headache
- • Nausea
- • Diarrhea
- • Trouble sleeping (insomnia)
- • Tiredness (fatigue)
- • Constipation (2%)
- Pain 1,425
- Anxiety 1,051
- Emotional Distress 1,048
- Anhedonia 942
- Chronic Kidney Disease 701
- Nausea 2,262
- Fatigue 1,733
- Diarrhoea 1,700
- Pain 1,481
- Headache 1,381
If you have both HIV-1 and hepatitis B, you should be tested for hepatitis B before starting Dovato. Using Dovato can cause the hepatitis B virus to become resistant to lamivudine. Stopping Dovato can also cause a severe worsening of hepatitis B. Your liver function should be checked regularly.
Inadvertent injection of sucralfate has led to fatal complications, including blood clots in the lungs and brain. Sucralfate is not intended for intravenous administration.
There is a pregnancy registry to monitor outcomes in people exposed to Dovato during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant. There may be a risk of neural tube defects if dolutegravir is taken at the time of conception.
It is not known if sucralfate can harm an unborn baby. Talk to your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Also Compare, Nearby Drugs
Compare dolutegravir/lamivudine with
How to Read This dolutegravir/lamivudine vs sucralfate Comparison
dolutegravir/lamivudine is classified in the Integrase Inhibitor / NRTI Combination drug class, while sucralfate sits within the Mucosal Protective Agent class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, dolutegravir/lamivudine has 5,167 submissions while sucralfate has 8,557. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to sucralfate contains minerals that can bind to dolutegravir in your stomach, preventing the medicine from being absorbed into your bloodstream.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for dolutegravir/lamivudine or sucralfate.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.